Investigational drug · Phase 2
Efesovir
Also called: FS-1
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Covid19.
Phase 2Last checked: Nov 19, 2026Latest source record: Apr 17, 2024 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
2
Any phase or sponsor naming "Efesovir"
First trial start
2025
Dec 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Efesovir", any sponsor or status.
Conditions studied
As listed on its trial records.
- Covid19
Approved drugs for the same conditions: Infectious disease and vaccines
Largest trials
Live from ClinicalTrials.gov: studies naming "Efesovir" as an intervention, largest first.
- FS-1 Drug for Treatment of Multiple Drug-resistant TuberculosisPivotal-lookingCompleted
Scientific Center for Anti-infectious Drugs, KazakhstanIndustry
NCT02607449 · 344 participants · Start Dec 2013 · Primary completion Aug 2020
Drug: FS-1; Placebo · For: Tuberculosis, MDR
Sites: Semey, Kazakhstan; Aktobe, Kazakhstan; Almaty, Kazakhstan · 6 sites in all
- "Efesovir" (FS-1) for COVID-19, Phase 2Not yet recruiting
Scientific Center for Anti-infectious Drugs, KazakhstanIndustry
NCT05060705 · 62 participants (planned) · Start Dec 2025 · Primary completion Apr 2026
Drug: Efesovir · For: Covid19
Sites: Semey, Kazakhstan
Newest research
PubMed records naming it or its code names, newest first.
- Contrasting atmospheric behavior of PCDD/Fs and PBDD/Fs in a subtropical megacity: Source characteristics, regional transport, and gas-particle partitioning.
Liu MY, Shang RJ, Huang LT, et al. · Environ Res 2026
- Correlation between serum IgG levels and labial gland pathological grading in patients with suspected Sjögren's syndrome: a cross-sectional analysis.
Yu L, Xu A, Hu S, et al. · Clin Rheumatol 2026
- Experimental study on micro-hole drilling in titanium felt using an ultrafast laser.
Chen Y, He J, Liu J, et al. · Appl Opt 2026
- Generation of 1.4-cycle, 1.85 μm pulses by multi-plate post-compression in ambient air.
Hu F, Huang Z, Peng J, et al. · Opt Lett 2026
- Isolation, Molecular Characterization, and Biological Control of Fusarium solani Causing Stem Rot of Durian Tree in China.
Jiang W, Wei H, Gao H, et al. · Pathogens 2026
- Diabetes and Femoral Fracture Patterns: A Nationwide Registry Study (1997-2021).
Bech AA, Kvist AV, Vestergaard P, et al. · Diabetes Care 2026
Also in development for Covid19
- EbselenSPI-1005Phase 33 trials
Sound Pharmaceuticals, Incorporated · Meniere's Disease, Ménière's Disease, Hearing Loss
- [18F]F-AraGPET tracer, 2'-deoxy-2'-fluoro-9-β-D-arabinofuranosylguaninePhase 22 trials
CellSight Technologies, Inc. · Alzheimer Disease (AD), Covid19, SARS-CoV Infection
- DactolisibBEZ235, RTB101Phase 22 trials
Restorbio Inc. · Respiratory Tract Infections, Covid19
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.